Remodeling of the tumor microenvironment by combined treatment with a novel radiosensitizer, α-sulfoquinovosylmonoacylglycerol (α-SQMG) and X-irradiation

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4397-4404

  Ohta, Keisuke ^a,b   Murata, Hiroshi ^b,c   Mori, Yoko ^a   Ishima, Masahiro ^a,b   Sugawara, Fumio ^c   Sakaguchi, Kengo ^c   Miura, Masahiko ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b CANGO Corp   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

SQMG; Angiogenesis; Hypoxia; Pericytes; Radiotherapy; Tumor microenvironment; Vascular normalization

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ALPHA SULFOQUINOVOSYLMONOACYLGLYCEROL; CD31 ANTIGEN; COLLAGEN TYPE 4; PIMONIDAZOLE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DENSITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PERICYTE; PRIORITY JOURNAL; RADIOSENSITIZATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; X IRRADIATION;

ADENOCARCINOMA; ANIMALS; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; GLYCOLIPIDS; HUMANS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; X-RAY THERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650239187     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Folkman J: Tumor angiogenesis: therapeutic implications. New Engl J Med 285: 1182-1186, 1971.
2. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
3. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
4. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP and McMahon G: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (FIk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99-106, 1999.
5. Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29(Suppl 16): 10-14, 2002.
6. O'Reilly MS: Targeting multiple biological pathways as a strategy to improve the treatment of cancer. Clin Cancer Res 8: 3309-3310, 2002.
7. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW and Weichselbaum RR: Combined effects of angiostatin and ionizing radiation in anti-tumor therapy. Nature 394: 287-291, 1998.
8. Vincenzi B, Santini D, Russo A, Spoto C, Venditti O, Gasparro S, Rizzo S, Zobel BB, Caricato M, Valeri S, Coppola R and Tonini G: Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. Cancer 115: 4849-4856, 2009.
9. Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY and Cheng AL: Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 102: 981-986, 2010.
10. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.
11. Jain RK, Duda DG, Clark JW and Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40, 2006.
12. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ and Jain RK: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64: 3731-3736, 2004.
13. Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergiin S and Schadendorf D: Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 207: 491-503, 2010.
14. McGee MC, Hamner JB, Williams RF, Rosati SF, Sims TL, Ng CY, Gaber MW, Calabrese C, Wu J, Nathwani AC, Duntsch C, Merchant TE and Davidoff AM: Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 76: 1537-1545, 2010.
15. Sahara H, Ishikawa M, Takahashi N, Ohtani S, Sato N, Gasa S, Akino T and Kikuchi K: In vivo anti-tumour effect of 3′-sulphonoquinovosyl 1′-monoacylglyceride isolated from sea urchin (Strongylocentrotus intermedius) intestine. Br J Cancer 75: 324-332, 1997.
16. Mizushina Y, Watanabe I, Ohta K, Takemura M, Sahara H, Takahashi N, Gasa S, Sugawara F, Matsukage A, Yoshida S and Sakaguchi K: Studies on inhibitors of mammalian DNA polymerase alpha and beta: sulfolipids from a pteridophyte, Athyrium niponicum. Biochem Pharmacol 55: 537-5341, 1998.
17. Ohta K, Mizushina Y, Hirata N, Takemura M, Sugawara F, Matsukage A, Yoshida, F and Sakaguchi K: Sulfoquinovosyl-diacylglycerol, KM043, a new potent inhibitor of eukaryotic DNA polymerases and HIV-reverse transcriptase type 1 from a marine red alga, Gigartina tenella. Chem Pharm Bull (Tokyo) 46: 684-686, 1998.
18. Sakimoto I, Ohta K, Yamazaki T, Ohtani S, Sahara H, Sugawara F, Sakaguchi K and Miura M: α-Sulfoquinovosylmonoacylglycerol is a novel potent radiosensitizer targeting tumor angiogenesis. Cancer Res 66: 2287-2295, 2006.
19. Sahara H, Hanashima S, Yamazaki T, Takahashi S, Sugawara F, Ohtani S, Ishikawa M, Mizushina Y, Ohta K, Shimozawa K, Gasa S, Jimbow K, Sakaguchi K, Sato N and Takahashi N: Anti-tumor effect of chemically synthesized sulfolipids based on sea urchin's natural sulfonoquinovosylmonoacylglycerols. Jpn J Cancer Res 93: 85-92, 2002.
20. Murakami C, Yamazaki T, Hanashima S, Takahashi S, Takemura M, Yoshida S, Ohta K, Yoshida H, Sugawara F, Sakaguchi K and Mizushina Y: A novel DNA polymerase inhibitor and a potent apoptosis inducer: 2-mono-O-acyl-3-O-(alpha-D- sulfoquinovosyl)-glyceride with stearic acid. Biochim Biophys Acta 1645: 72-80, 2003.
21. Hall EJ and Giaccia AJ: Oxygen effect and reoxygenation. In: Radiobiology for the Radiologist, 6th edn. Hall EJ and Giaccia AJ (eds.). Philadelphia, Lippincott Williams & Wilkins, pp. 85-105, 2006.
22. Masunaga S, Ono K, Wandl EO, Fushiki M and Abe M: Use of the micronucleus assay for the selective detection of radiosensitivity in BUdR-unincorporated cells after pulse-labelling of exponentially growing tumour cells. Int J Radiat Biol 58: 303-311, 1990.
23. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ and Schilsky RL and Goldberg RM: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617-3622, 2010.
24. Hall EJ and Giaccia AJ: Radiosensitizers and bioreductive drugs. In: Radiobiology for the Radiologist, 6th edn. Hall EJ and Giaccia AJ (eds.). Philadelphia, Lippincott Williams & Wilkins, pp. 419-431, 2006.